Skip to content

Independent register of U.S. FDA drug recalls · updated Oct 10, 2026

FDA Drug Recalls

18,003 recalls, newest first

Oct 1, 2019 Class III · Low risk

Motion Sickness Strips

Subpotent Drug

Terminated Wrong potency / content Sato Pharmaceutical Inc. NDC 69842-288-01 D-0325-2020

Oct 1, 2019 Class III · Low risk

Wal-Dram 2

Subpotent Drug

Terminated Wrong potency / content Sato Pharmaceutical Inc. NDC 0363-1407-01 D-0324-2020

Oct 1, 2019 Class III · Low risk

Motion Sickness

Subpotent Drug

Terminated Wrong potency / content Sato Pharmaceutical Inc. NDC 59779-534-01 D-0323-2020

Oct 1, 2019 Class III · Low risk

Zentrip (meclizine Hydrochloride)

Subpotent Drug

Terminated Wrong potency / content Sato Pharmaceutical Inc. NDC 49873-803-01 D-0322-2020

Oct 1, 2019 Class III · Low risk

Sankaijo BOTANICAL LAXATIVE

Subpotent Drug: Formulated amount of sennosides component is less than labelled claim.

Terminated Wrong potency / content Sato Pharmaceutical Inc. NDC 49873-404-01 D-0303-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0185-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 63868-480-24 D-0184-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0131-30 D-0183-2020

Oct 1, 2019 Class II · Moderate risk

Dr. Reddy's Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 55111-404-34 D-0182-2020

Oct 1, 2019 Class II · Moderate risk

Dr. Reddy's Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 55111-131-60 D-0181-2020

Oct 1, 2019 Class II · Moderate risk

Dr. Reddy's Ranitidine Capsules

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 55111-130-30 D-0180-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 11673-849-40 D-0179-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0178-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 71713-203-02 D-0177-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 43598-808-62 D-0176-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets 75 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 63868-482-30 D-0175-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-131-30 D-0174-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 69842-871-30 D-0173-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-505-34 D-0172-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 49035-404-61 D-0171-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0010-34 D-0170-2020

Oct 1, 2019 Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0169-2020

Oct 1, 2019 Class II · Moderate risk

Dr. Reddy's: Ranitidine Capsules 150 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 55111-129-60 D-0168-2020

Sep 27, 2019 Class II · Moderate risk

Children's Ibuprofen Oral Suspension USP

Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Terminated Particulate / foreign matter Taro Pharmaceuticals U.S.A., Inc. NDC 67091-321-04 D-0302-2020

Sep 27, 2019 Class II · Moderate risk

Children's Ibuprofen Oral Suspension USP

Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Terminated Particulate / foreign matter Taro Pharmaceuticals U.S.A., Inc. NDC 51672-2130-1 D-0301-2020

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061